Clinical trials: Coronary Vessel
Acute Coronary Syndrome, Myocardial Infarction
RAMP 200 / RAMP Cardiovascular Tests at the Point-of-Care
This clinical investigation is designed to demonstrate the performance characteristics of the RAMP® cardiac tests analyzed on the RAMP® 200 by non-laboratorial Operators at the point-of-care when compared to the results for the…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Heart Failure, Congestive Heart Failure
- Trial name
- C-POC (NCT02191735)
- Testing
- RAMP 200, RAMP Reader
- Where
- 3 sites in United States
- Volunteers
- 719 people
- Sponsor
- Response Biomedical Corp.
Coronary Artery Disease
DESolve Post-Approval Study
To evaluate the long-term safety and performance of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System
- Trial name
- NCT02013349
- Testing
- coronary intervention
- Where
- 7 sites in Germany, Italy and 1 more
- Volunteers
- 102 people
- Sponsor
- Elixir Medical Corporation
Ischemic Heart Disease, Myocardial Ischemia
To Evaluate The Safety and Efficacy of 'AVI' Stent Comparing With Firebird2® For Treating Coronary Revascularization
To evaluate The Safety and Efficacy of 'AVI' Stent Comparing with Firebird2® For Treating Coronary Revascularization.
- Conditions
- Ischemic Heart Disease, Myocardial Ischemia, Coronary Disease, Acute Coronary Syndrome
- Trial name
- NCT02133287
- Testing
- AVI® Arsenic trioxide drug eluting stent delivery system, Firebird2® sirolimus eluting stent system
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Beijing AmsinoMed Medical Device Co., Ltd
Cardiovascular Disease
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
The purpose of this study is to see whether subjects with gout who receive febuxostat or allopurinol for up to 9 years have a higher rate of serious heart and blood vessel complications (major cardiovascular events).
- Trial name
- CARES (NCT01101035)
- Testing
- Febuxostat, Allopurinol
- Where
- 203 sites in United States, Mexico
- Volunteers
- 6,198 people
- Sponsor
- Takeda
Atherosclerosis, Coronary Artery Disease
A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™)
Compile acute (30-day) clinical outcomes data and 9-month angiographic and intravascular ultrasound (IVUS) data for the PROMUS Element™ Everolimus- Eluting Coronary Stent System in the treatment of patients with a single de novo…
- Trial name
- PLATINUM QCA (NCT00824434)
- Testing
- PROMUS Element™
- Where
- 17 sites in Australia, Malaysia and 2 more
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
PFO, PFO - Patent Foramen Ovale
Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study
The goal of this clinical trial is to test a new heart device called P3 Occluder System in patients who have a small opening between the upper chambers of the heart (called a Patent Foramen Ovale or PFO) and have experienced a…
- Conditions
- PFO, PFO - Patent Foramen Ovale, Cryptogenic Stroke, Patent Foramen Ovale
- Trial name
- PROTEA-PFO (NCT07172464)
- Testing
- Recross P3 Occluder (P3O) System
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Recross Cardio, Inc.
Acute Coronary Syndrome
Trial for the Use of Pretest Probability to Reduce Unnecessary Testing for Low-Risk Patients With Chest Pain
The purpose of this study is to evaluate if the implementation of quantitative pretest probability assessment will significantly reduce the unnecessary use of the intra-emergency department chest pain center.
- Trial name
- NCT00243516
- Testing
- PREtest Consult
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- PREtest Consult
Diabetes Mellitus, Type 2
A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in Portugal
This study aims to estimate the number of patients with cardiovascular disease and risk factors in patients who had been diagnosed with type 2 diabetes mellitus.
- Trial name
- PICT2RE (NCT03797885)
- Testing
- No treatment given
- Where
- 14 sites in Portugal
- Volunteers
- 730 people
- Sponsor
- Novo Nordisk A/S
Stroke, Patent Foramen Ovale
AMPLATZER PFO Occluder Post Approval Study
The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Setting.
- Trial name
- PFO PAS (NCT03309332)
- Testing
- AMPLATZER™ PFO Occluder
- Where
- 88 sites in United States, Canada and 5 more
- Volunteers
- 1,214 people
- Sponsor
- Abbott Medical Devices
Cardiomyopathies, Heart Failure, Congestive
A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care Therapy
The purpose of this pilot study is to compare the clinical effects, safety profile, and economic impact of standard therapy plus Natrecor® (nesiritide, a recombinant form of the natural human peptide normally secreted by the…
- Conditions
- Cardiomyopathies, Heart Failure, Congestive, Dyspnea, Paroxysma
- Trial name
- NCT00270387
- Testing
- Natrecor (nesiritide)
- Volunteers
- 250 people
- Sponsor
- Scios, Inc.
Coronary Artery Disease
CSI Percutaneous Ventricular Assist Device (pVAD) Second in Human Study
The purpose of this study is to collect data on safety and device performance on the CSI pVAD System used to support hemodynamic stability during HR-PCIs to inform device design and finalization.
- Trial name
- NCT05695716
- Testing
- CSI pVAD System
- Where
- Georgia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Post-Approval Study of PROMUS Element™ in China
The purpose of this study is to compile real-world clinical outcomes data for the PROMUS Element™ and PROMUS Element™ Plus Everolimus-Eluting Coronary Stent System (PROMUS Element and PROMUS Element Plus Stent System) in routine…
- Trial name
- PEChina (NCT01677585)
- Where
- China
- Volunteers
- 2,016 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
French Post-Marketing Surveillance Survey
To assess the safety and effecacy of the Cypher stent ™ \& Cypher Select ™ in the normal use of medical practices, within the labeled indications.
- Trial name
- FR E-REGISTRY (NCT00855478)
- Testing
- Cypher stent ™ or Cypher Select ™
- Volunteers
- 4,080 people
- Sponsor
- Cordis US Corp.
Aortic Diseases
INFLATE Study: Investigation of the Safety and Performance of a Novel PTV Balloon in Patients Undergoing TAVI for Severe Aortic Stenosis
This clinical investigation is being done to evaluate the safety and effectiveness of a new device, a PTV Balloon, that will be used to open up an area in the heart (the valve) before and potentially after placing a new valve in…
- Trial name
- NCT06816485
- Testing
- PTV (Percutaneous Transcatheter Valvuloplasty) Balloon
- Where
- 9 sites in Spain
- Volunteers
- 93 people
- Sponsor
- Biosensors Europe SA
Refractory Angina Pectoris
Efficacy of Extracorporeal Shockwave Myocardial Revascularization
Clinical research to justify effectiveness of the Extracorporeal Shockwave Myocardial Revascularization (ESMR) Therapy for treatment of patients with reversible myocardial ischemia secondary to Coronary Artery Disease (CAD) and…
- Trial name
- ANGEL (NCT01711099)
- Testing
- device for Extracorporeal Shockwave Myocardial Revascularization (ESMR) therapy
- Where
- 2 sites in Hungary
- Volunteers
- 14 people
- Sponsor
- Salus Ltd.
ACS, Acute Coronary Syndrome
Study Evaluating How Patients With Acute Coronary Syndrome Are Managed During 2 Years After Discharge
The aim of this international study is to describe the short- and long-term (i.e. up to 2 years following the index event) antithrombotic management patterns (AMPs) in patients hospitalized for acute coronary syndromes (ST…
- Conditions
- ACS, Acute Coronary Syndrome, Myocardial Infarction, Unstable Angina
- Trial name
- EPICOR (NCT01171404)
- Where
- 410 sites in Argentina, Belgium and 18 more
- Volunteers
- 10,568 people
- Sponsor
- AstraZeneca
Coronary Artery Disease, Cardiovascular Diseases
Functional Diagnostic Accuracy of Quantitative Flow Ratio in Tandem Lesions and Virtual Stenting
Quantitative Flow Ratio (QFR) is a novel method for evaluating the functional significance of coronary stenosis. Virtual stent implantation technique combined with QFR was recently developed to predict the functional significance…
- Conditions
- Coronary Artery Disease, Cardiovascular Diseases, Myocardial Ischemia, Arterial Occlusive Diseases
- Trial name
- FORTRESS (NCT03405506)
- Testing
- Quantitative Flow Ratio (QFR)
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Pulse Medical Imaging Technology (Shanghai) Co., Ltd
Angina, Unstable, Myocardial Infarction
Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome
To compare efficacy and safety of dalteparin compared to unfractionated heparin in patients of non ST elevation acute coronary syndromes who are planned to undergo coronary interventions (angioplasty or bypass surgery)
- Trial name
- NCT00435487
- Testing
- Dalteparin ( Fragmin), Unfractionated heparin
- Where
- 8 sites in India
- Volunteers
- 173 people
- Sponsor
- Pfizer
Atherosclerosis, Percutaneous Coronary Intervention
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
The study is designed to compare the efficacy and safety profile of cangrelor to standard of care in patients require percutaneous coronary intervention (PCI).
- Conditions
- Atherosclerosis, Percutaneous Coronary Intervention, Acute Coronary Syndrome
- Trial name
- CHAMPION (NCT01156571)
- Testing
- cangrelor P2Y12 (platelet) inhibitor, Clopidogrel - 300 or 600 mg (study arm), Clopidogrel 600 mg post cangrelor
- Where
- United States
- Volunteers
- 11,145 people
- Sponsor
- The Medicines Company
Ischemic Heart Disease
Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study
This is a six (6) month, randomized, un-blinded, study to assess the safety and performance of the Palmaz Mach-5 Grooved Coronary Stent System vs. the Palmaz Bare Metal Coronary Stent System.
- Trial name
- NCT02759406
- Testing
- coronary stent
- Volunteers
- 48 people
- Sponsor
- Palmaz Scientific
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.